• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血浆神经丝轻链升高与阿尔茨海默病特征区域的多模态神经影像学特征相关,并可预测未来的tau 沉积。

Elevated plasma neurofilament light was associated with multi-modal neuroimaging features in Alzheimer's disease signature regions and predicted future tau deposition.

机构信息

Department of Imaging, The Fifth People's Hospital of Shanghai, Fudan University, No.128 Ruili Road, Minhang District, Shanghai, 200240, China.

出版信息

BMC Neurol. 2024 Jul 6;24(1):236. doi: 10.1186/s12883-024-03728-7.

DOI:10.1186/s12883-024-03728-7
PMID:38971733
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11227162/
Abstract

BACKGROUND

Neurofilament Light (NfL) is a biomarker for early neurodegeneration in Alzheimer's disease (AD). This study aims to examine the association between plasma NfL and multi-modal neuroimaging features across the AD spectrum and whether NfL predicts future tau deposition.

METHODS

The present study recruited 517 participants comprising Aβ negative cognitively normal (CN-) participants (n = 135), Aβ positive cognitively normal (CN +) participants (n = 64), individuals with amnestic mild cognitive impairment (aMCI) (n = 212), and those diagnosed with AD dementia (n = 106). All the participants underwent multi-modal neuroimaging examinations. Cross-sectional and longitudinal associations between plasma NfL and multi-modal neuro-imaging features were evaluated using partial correlation analysis and linear mixed effects models. We also used linear regression analysis to investigate the association of baseline plasma NfL with future PET tau load. Mediation analysis was used to explore whether the effect of NfL on cognition was mediated by these imaging biomarkers.

RESULTS

The results showed that baseline NfL levels and the rate of change were associated with Aβ deposition, brain atrophy, brain connectome, glucose metabolism, and brain perfusion in AD signature regions (P<0.05). In both Aβ positive CN and MCI participants, baseline NfL showed a significant predictive value of elevating tau burden in the left medial orbitofrontal cortex and para-hippocampus (β = 0.336, P = 0.032; β = 0.313, P = 0.047). Lastly, the multi-modal neuroimaging features mediated the association between plasma NfL and cognitive performance.

CONCLUSIONS

The study supports the association between plasma NfL and multi-modal neuroimaging features in AD-vulnerable regions and its predictive value for future tau deposition.

摘要

背景

神经丝轻链(NfL)是阿尔茨海默病(AD)早期神经退行性变的生物标志物。本研究旨在探讨 AD 谱中血浆 NfL 与多模态神经影像学特征之间的关联,以及 NfL 是否可以预测未来的 tau 沉积。

方法

本研究共招募了 517 名参与者,包括 Aβ阴性认知正常(CN-)参与者(n=135)、Aβ阳性认知正常(CN+)参与者(n=64)、遗忘型轻度认知障碍(aMCI)个体(n=212)和 AD 痴呆诊断患者(n=106)。所有参与者均接受了多模态神经影像学检查。采用偏相关分析和线性混合效应模型评估了血浆 NfL 与多模态神经影像学特征之间的横断面和纵向关联。我们还使用线性回归分析探讨了基线血浆 NfL 与未来 PET tau 负荷之间的关联。采用中介分析来探讨 NfL 对认知的影响是否通过这些影像学生物标志物介导。

结果

结果显示,基线 NfL 水平和变化率与 AD 特征区域的 Aβ 沉积、脑萎缩、脑连接组、葡萄糖代谢和脑灌注相关(P<0.05)。在 Aβ 阳性 CN 和 MCI 参与者中,基线 NfL 对左侧内侧眶额皮质和海马旁回 tau 负荷升高具有显著的预测价值(β=0.336,P=0.032;β=0.313,P=0.047)。最后,多模态神经影像学特征介导了血浆 NfL 与认知表现之间的关联。

结论

该研究支持了 AD 易感区域中血浆 NfL 与多模态神经影像学特征之间的关联及其对未来 tau 沉积的预测价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0a/11227162/824a06bc39e6/12883_2024_3728_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0a/11227162/0f340fc486bb/12883_2024_3728_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0a/11227162/ce95479feccc/12883_2024_3728_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0a/11227162/7706d4dffad6/12883_2024_3728_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0a/11227162/f3bf99068d90/12883_2024_3728_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0a/11227162/77fae1823ad6/12883_2024_3728_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0a/11227162/824a06bc39e6/12883_2024_3728_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0a/11227162/0f340fc486bb/12883_2024_3728_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0a/11227162/ce95479feccc/12883_2024_3728_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0a/11227162/7706d4dffad6/12883_2024_3728_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0a/11227162/f3bf99068d90/12883_2024_3728_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0a/11227162/77fae1823ad6/12883_2024_3728_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0a/11227162/824a06bc39e6/12883_2024_3728_Fig6_HTML.jpg

相似文献

1
Elevated plasma neurofilament light was associated with multi-modal neuroimaging features in Alzheimer's disease signature regions and predicted future tau deposition.血浆神经丝轻链升高与阿尔茨海默病特征区域的多模态神经影像学特征相关,并可预测未来的tau 沉积。
BMC Neurol. 2024 Jul 6;24(1):236. doi: 10.1186/s12883-024-03728-7.
2
Elevated plasma neurofilament light was associated with multi-modal neuroimaging features in Alzheimer's Disease signature regions and predicted future tau deposition.血浆神经丝轻链升高与阿尔茨海默病特征区域的多模态神经影像学特征相关,并预测未来tau蛋白沉积。
Res Sq. 2024 Feb 19:rs.3.rs-3946421. doi: 10.21203/rs.3.rs-3946421/v1.
3
Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.血浆神经丝轻链与阿尔茨海默病影像学生物标志物的阶段特异性关联。
Brain. 2020 Dec 1;143(12):3793-3804. doi: 10.1093/brain/awaa342.
4
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.阿尔茨海默病患者纵向血浆神经丝轻链与神经退行性变的关系。
JAMA Neurol. 2019 Jul 1;76(7):791-799. doi: 10.1001/jamaneurol.2019.0765.
5
Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition.纵向血浆 p-tau181 和 NfL 与 tau-PET、Aβ-PET 和认知的关联。
J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1289-1295. doi: 10.1136/jnnp-2020-325537. Epub 2021 Jun 29.
6
Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients.比较血浆和神经影像学生物标志物以预测非痴呆记忆门诊患者的认知下降。
Alzheimers Res Ther. 2024 May 16;16(1):110. doi: 10.1186/s13195-024-01478-9.
7
Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.阿尔茨海默病中血液磷酸化 tau181 和神经丝轻链与神经退行性变的纵向关联。
JAMA Neurol. 2021 Apr 1;78(4):396-406. doi: 10.1001/jamaneurol.2020.4986.
8
Predicting Longitudinal Cognitive Decline and Alzheimer's Conversion in Mild Cognitive Impairment Patients Based on Plasma Biomarkers.基于血浆生物标志物预测轻度认知障碍患者的纵向认知下降和阿尔茨海默病转化。
Cells. 2024 Jun 22;13(13):1085. doi: 10.3390/cells13131085.
9
Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.阿尔茨海默病患者血浆神经丝轻链与神经退行性变的关联
JAMA Neurol. 2017 May 1;74(5):557-566. doi: 10.1001/jamaneurol.2016.6117.
10
Tau pathology mediated the plasma biomarkers and cognitive function in patients with mild cognitive impairment.tau 病理学介导了轻度认知障碍患者的血浆生物标志物和认知功能。
Exp Gerontol. 2024 Oct 1;195:112535. doi: 10.1016/j.exger.2024.112535. Epub 2024 Aug 15.

引用本文的文献

1
Potential Mediating Role of Polygenic Hazard Score in the Association Between Neurofilament Light Chain and Default Mode Network Connectivity Across the Alzheimer's Disease Continuum.多基因风险评分在阿尔茨海默病连续体中神经丝轻链与默认模式网络连通性之间关联中的潜在中介作用。
IBRO Neurosci Rep. 2025 May 1;18:732-738. doi: 10.1016/j.ibneur.2025.04.018. eCollection 2025 Jun.
2
Stem Cell Therapy for the Treatment of Amyotrophic Lateral Sclerosis: Comparison of the Efficacy of Mesenchymal Stem Cells, Neural Stem Cells, and Induced Pluripotent Stem Cells.干细胞疗法治疗肌萎缩侧索硬化症:间充质干细胞、神经干细胞和诱导多能干细胞疗效比较
Biomedicines. 2024 Dec 27;13(1):35. doi: 10.3390/biomedicines13010035.
3

本文引用的文献

1
CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly.脑脊液免疫激活生物标志物与阿尔茨海默病用于预测老年人认知障碍风险。
Sci Adv. 2024 Apr 5;10(14):eadk3674. doi: 10.1126/sciadv.adk3674. Epub 2024 Apr 3.
2
The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease.使用脑脊液中的突触生物标志物来区分行为变异型额颞叶痴呆与原发性精神障碍和阿尔茨海默病。
Alzheimers Res Ther. 2024 Feb 14;16(1):34. doi: 10.1186/s13195-024-01409-8.
3
Plasma Markers of Alzheimer's Disease Pathology, Neuronal Injury, and Astrocytic Activation and MRI Load of Vascular Pathology and Neurodegeneration: The SMART-MR Study.
Blood-Based Biomarkers in Alzheimer's Disease: Advancing Non-Invasive Diagnostics and Prognostics.
阿尔茨海默病的血液生物标志物:推进非侵入性诊断和预后评估。
Int J Mol Sci. 2024 Oct 10;25(20):10911. doi: 10.3390/ijms252010911.
阿尔茨海默病病理学、神经元损伤、星形胶质细胞激活的血浆标志物以及血管病理学和神经退行性变的MRI负荷:SMART-MR研究
J Am Heart Assoc. 2024 Feb 20;13(4):e032134. doi: 10.1161/JAHA.123.032134. Epub 2024 Feb 14.
4
Probing neural circuit mechanisms in Alzheimer's disease using novel technologies.利用新技术探究阿尔茨海默病的神经回路机制。
Mol Psychiatry. 2023 Oct;28(10):4407-4420. doi: 10.1038/s41380-023-02018-x. Epub 2023 Mar 23.
5
Brain network decoupling with increased serum neurofilament and reduced cognitive function in Alzheimer's disease.阿尔茨海默病患者血清神经丝蛋白升高和认知功能下降导致的脑网络解耦。
Brain. 2023 Jul 3;146(7):2928-2943. doi: 10.1093/brain/awac498.
6
Inflammation Disrupts Cognitive Integrity via Plasma Neurofilament Light Chain Coupling Brain Networks in Alzheimer's Disease.炎症通过阿尔茨海默病患者血浆神经丝轻链连接大脑网络破坏认知完整性。
J Alzheimers Dis. 2022;89(2):505-518. doi: 10.3233/JAD-220475.
7
Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders.全面的横断面和纵向分析血浆神经丝轻链在额颞叶痴呆谱系障碍中的变化。
Cell Rep Med. 2022 Apr 19;3(4):100607. doi: 10.1016/j.xcrm.2022.100607.
8
Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer's disease.阿尔茨海默病中海马亚区微结构及其与血浆生物标志物的关系。
Brain. 2022 Jun 30;145(6):2149-2160. doi: 10.1093/brain/awac138.
9
Plasma neurofilament light levels correlate with white matter damage prior to Alzheimer's disease: results from ADNI.血浆神经丝轻链水平与阿尔茨海默病前的白质损伤相关:来自 ADNI 的结果。
Aging Clin Exp Res. 2022 Oct;34(10):2363-2372. doi: 10.1007/s40520-022-02095-y. Epub 2022 Feb 28.
10
Diagnostic Blood Biomarkers in Alzheimer's Disease.阿尔茨海默病的诊断性血液生物标志物
Biomedicines. 2022 Jan 13;10(1):169. doi: 10.3390/biomedicines10010169.